Want to see OLYMY full AI Analyst Report?
Earnings Data
Report Date
Aug 12, 2026TBA (Confirmed)
Period Ending
2027 (Q1)Consensus EPS Forecast
0.06Last Year’s EPS
0.05Same Quarter Last Year
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call balanced significant near-term operational and regulatory challenges (FDA observations, product ship holds, one-off gross margin/COGS impacts, and increased restructuring provisioning) against clear signs of stabilization and management actions (China recovery, majority of products released, leadership changes, disciplined commercial remediation and maintained mid-term targets). Management emphasized these are addressable, one-off or execution-related issues and reiterated long-term margin and growth ambitions, but material short-term impacts keep the tone cautious.Company Guidance
China: Early Signs of Recovery
After several quarters of double-digit declines, China showed a turnaround with approximately 5–6% growth quarter-over-quarter following tightened go-to-market focus, local investments and weekly pipeline oversight.
Majority of Ship-Held Products Returned to Market
Management reported that ~70% of products placed on ship hold have been released back into markets after patient-safety reviews; ~30% remain under remediation.
Mid-term Plan and Margin Commitment Intact
Management reiterated the midterm '3,4,5' plan and the target of >100 basis points of annual margin improvement beginning FY27, maintaining the longer-term goal of mid-single-digit revenue growth and 20%+ operating margin.
Leadership Actions to Drive Execution
New senior appointments (new President of China Rosa Chen, global operations lead David Shan, and continued CTO leadership) aimed at strengthening go-to-market execution, operations and R&D; management emphasized building Japanese leadership depth as well.
Commercial Execution Plan for U.S. GI
Management identified U.S. GI underperformance as an execution/pipeline conversion issue (not a competitiveness problem) and outlined disciplined pipeline management and oversight actions to restore growth, expressing confidence in returning to growth in Q4.
Guidance Presented Transparently as Ranges
Company moved to range-based guidance to reflect dynamic factors (product releases timing, pipeline conversion) and stated ranges do not assume additional ship holds.
OLYMY Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
OLYMY Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 12, 2026 | $9.88 | $9.77 | -1.08% |
Feb 13, 2026 | $12.80 | $12.10 | -5.50% |
Nov 07, 2025 | $12.02 | $12.22 | +1.70% |
Aug 08, 2025 | $12.14 | $12.34 | +1.62% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Olympus (OLYMY) report earnings?
Olympus (OLYMY) is schdueled to report earning on Aug 12, 2026, TBA (Confirmed).
What is Olympus (OLYMY) earnings time?
Olympus (OLYMY) earnings time is at Aug 12, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is OLYMY EPS forecast?
OLYMY EPS forecast for the fiscal quarter 2027 (Q1) is 0.06.